StreetInsider.com News Articles

Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

Thu, 15 Oct 2026 09:20:00 -0400

CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027

Recent deal activity and emerging clinical data highlighting limitations of current ADC sequencing reinforce the increasing demand for novel ADC payloads

Access the Akari CEO Corner here

TAMPA, Fla. and LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today released a new CEO Corner segment

Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

Thu, 15 Oct 2026 09:20:00 -0400

CEO Abizer Gaslightwala discusses Akari’s novel PH1 payload strategy and execution priorities supporting AKTX-101’s advancement toward planned Phase 1 clinical development in mid-2027

Recent deal activity and emerging clinical data highlighting limitations of current ADC sequencing reinforce the increasing demand for novel ADC payloads

Access the Akari CEO Corner here

Akari Therapeutics names Vatnak Vat-Ho as chief business officer

Tue, 13 Oct 2026 09:02:57 -0400

Akari Therapeutics, Plc (NASDAQ: AKTX) appointed Vatnak Vat-Ho as chief business officer, the oncology biotechnology company announced Oct. 13, 2026.

Vat-Ho brings more than 20 years of experience in oncology business development, biopharmaceutical strategy, equity research and healthcare investing. He has held senior roles in transactions totaling more than $25 billion in aggregate value, involving companies including Pfizer, Exelixis, BioNTech, Merck KGaA, Roivant and Roche/Genentech.

Most recently, Vat-Ho served as chief business officer and a member of the management board at Ryvu Therapeutics, where he originated and closed a collaboration with Exelixis involving a novel antibody drug conjugate (ADC) payload and a

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Tue, 13 Oct 2026 09:01:00 -0400

Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value

Mr. Vat-Ho brings highly relevant ADC payload partnering experience, including recently executed collaborations with Exelixis and BioNTech

TAMPA, Fla. and LONDON, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the appointment of Vatnak Vat-Ho as Chief Business Officer, strengthening the Company’s leadership team with

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Tue, 13 Oct 2026 09:01:00 -0400

Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value

Mr. Vat-Ho brings highly relevant ADC payload partnering experience, including recently executed collaborations with Exelixis and BioNTech

Akari Therapeutics files PCT patent for RNA splicing ADC payload PH1

Thu, 01 Oct 2026 08:26:46 -0400

Akari Therapeutics, Plc (Nasdaq: AKTX) has filed a PCT patent application, PCT/US2026/45955, covering its proprietary antibody drug conjugate payload PH1 and its ability to disrupt multiple alternative RNA splicing pathways associated with cancer progression, according to a company statement.

The filing expands on Akari's existing patent portfolio related to its Thailanstatin-derived payload. Unlike conventional ADC payloads that rely on tubulin inhibition or DNA damage, PH1 targets the spliceosome, the cellular machinery responsible for RNA splicing. Cancer cells exploit alternative splicing to produce protein variants that support tumor growth and resistance to treatment.

The new application includes claims covering three specific splicing-related mechanisms.

Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

Thu, 01 Oct 2026 08:25:00 -0400

Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism

Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform

TAMPA, Fla. and LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955, expanding the Company’s growing intellectual property portfolio around its novel splicing-modulating payload, PH1 and PH1-based ADCs.

Alternative splicing enables cells to generate different

Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

Thu, 01 Oct 2026 08:25:00 -0400

Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism

Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform

Alternative splicing enables cells to generate different

Akari Therapeutics to present ADC platform at five September conferences

Tue, 08 Sep 2026 09:16:19 -0400

Akari Therapeutics, Plc (Nasdaq: AKTX) announced it has been selected to present at five oncology, ADC, and healthcare conferences in the United States and China during September 2026, according to a company statement.

President and CEO Abizer Gaslightwala will represent the company across the events, which include the Oncology & Immunology Innovation Partnering & Licensing Summit in Boston (Sept. 9–10), BioCon China 2026 in Shanghai (Sept. 15–16), the 2026 Global XDC Innovation Conference in Wuxi, China (Sept. 17–19), the H.C. Wainwright 28th Annual Global Investment Conference in New York (Sept. 14–16), and the 5th Annual ROTH Healthcare Opportunities Conference in New

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Tue, 08 Sep 2026 09:15:00 -0400

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September

CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations

TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that the Company has been selected to participate in five prominent oncology, ADC and healthcare industry and investor conferences in the United States and

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Tue, 08 Sep 2026 09:15:00 -0400

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September

CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference